Analysis
Stem cell funding’s ‘valley of death’
ANALYSIS: The California stem cell agency this week is tooting a $150 million horn and heralding its efforts to assist stem cell businesses with development of therapies that could ease the travails of everything from cancer to blindness. It is all about a financial “valley of death” that can imperil biotech firms as they seek to turn research into an actual product that can be used by patients.